PBM PSYENCE BIOMEDICAL LTD.


$ 2.36 $ -0.27 (-10.23 %)    

Friday, 06-Dec-2024 15:23:02 EST
QQQ $ 525.87 $ 4.67 (0.89 %)
DIA $ 447.30 $ -1.52 (-0.34 %)
SPY $ 607.78 $ 1.15 (0.19 %)
TLT $ 94.35 $ 0.14 (0.15 %)
GLD $ 242.95 $ 0.09 (0.04 %)
$ 2.37
$ 2.24
$ 0.00 x 0
$ 0.00 x 0
-- - --
$ 2.13 - $ 323.25
1,400,097
na
423,145
$ 31.24
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Independent valuation of PsyLabs values Psyence Biomed's stake at approximately $2 million, doubling in valueDebt-for-equit...

 psyence-biomedical-secures-extension-to-meet-nasdaq-compliance-standards

Psyence Biomed secures Nasdaq extension to meet compliance by December 31, advancing psilocybin-based therapeutics for mental h...

Core News & Articles

Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced an effective date for ...

Core News & Articles

Empax Center brings significant expertise in clinical trial execution for mental health and neurological conditionsPsyence Biom...

Core News & Articles

Following the successful export of its psilocybin extract to its CDMO in the UK, PsyLabs has now entered phase two of its devel...

Core News & Articles

Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company"), a developer of psilocybin-based thera...

Core News & Articles

- Reuters 

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION